Haptoglobin Phenotype and Cardiovascular Risk: The ACCORD Blood Pressure RCT

Area of Science:

• Cardiovascular Medicine
• Genetics
• Endocrinology

Background:

• Hypertension is a known risk factor for cardiovascular disease (CVD), coronary artery disease (CAD), and stroke in type 2 diabetes.
• Previous trials on intensive blood pressure control have yielded conflicting results regarding cardiovascular event reduction.
• The haptoglobin (Hp) phenotype might be an unmeasured biological factor influencing these outcomes.

Purpose of the Study:

• To investigate the association between intensive blood pressure control and cardiovascular events stratified by haptoglobin (Hp) phenotype.
• To explore whether Hp phenotype influences the effectiveness of intensive blood pressure management in reducing cardiovascular risk in type 2 diabetes.

Main Methods:

• Analysis of data from the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial.
• Utilized multivariable-adjusted Cox proportional hazards regression models.
• Stratified analysis comparing intensive versus standard blood pressure control in participants with the Hp2-2 phenotype and Hp1 allele carriers.

Main Results:

• Intensive blood pressure therapy significantly lowered composite CVD risk in Hp1 allele carriers (HR, 0.76), but not in Hp2-2 phenotype participants (HR, 1.12).
• A significant reduction in stroke risk was observed with intensive therapy in Hp1 carriers (HR, 0.53), but not in Hp2-2 participants.
• No significant differences in CAD risk reduction were found between the groups with intensive versus standard therapy.

Conclusions:

• The variable response to intensive blood pressure control observed in the ACCORD trial may be partly explained by differences in haptoglobin phenotypes.
• Further research and replication are necessary to confirm the role of Hp phenotypes in modulating cardiovascular outcomes in type 2 diabetes.